Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Nutrition > 2026 Vol. 1 > No. 2 > 100022
Next Article Previous Article
COMMENTARY   Open Access     Cite

In vivo PCSK9 base editing: From the concept of lifelong lipid lowering to early clinical exploration of one-time therapy

  • 1.

    State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province; Department of Cardiology, Qilu Hospital of Shandong University, Jinan 250012, China

  • 2.

    Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China

  • 3.

    These authors contributed equally

More Information
  • Corresponding authors: zhangyun@sdu.edu.cn (Y.Z.)
  • Received Date:  June 26, 2026
    Accepted Date:  July 06, 2026
    Published Online:  July 09, 2026
The Innovation Nutrition  1(2),  https://doi.org/10.59717/j.xinn-nutri.2026.100022  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Baigent C., Blackwell L., Emberson J., et al. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670−1681. DOI:10.1016/s0140-6736(10)61350-5

    View in Article CrossRef Google Scholar

    [2] Sabatine M. S., Giugliano R. P., Keech A. C., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376:1713−1722. DOI:10.1056/NEJMoa1615664

    View in Article CrossRef Google Scholar

    [3] Vafai S. B., Täubel J., Ashdown T., et al. (2026). In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. N. Engl. J. Med. DOI: 10.1056/NEJMoa2601283.

    View in Article Google Scholar

    [4] Cohen J. C., Boerwinkle E., Mosley T. H., Jr., et al(2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264−1272. DOI:10.1056/NEJMoa054013

    View in Article CrossRef Google Scholar

    [5] Beheshti S. O., Madsen C. M., Varbo A., et al. (2020). Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects. JACC 75:2553−2566. DOI:10.1016/j.jacc.2020.03.057

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Xue F., Liu S., Zhang C., et al. (2026). In vivo PCSK9 base editing: From the concept of lifelong lipid lowering to early clinical exploration of one-time therapy. The Innovation Nutrition 1:100022. https://doi.org/10.59717/j.xinn-nutri.2026.100022
    Xue F., Liu S., Zhang C., et al. (2026). In vivo PCSK9 base editing: From the concept of lifelong lipid lowering to early clinical exploration of one-time therapy. The Innovation Nutrition 1:100022. https://doi.org/10.59717/j.xinn-nutri.2026.100022

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
    Tables(1)

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(749) PDF downloads(105)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.